Putative allosteric MEK1 and MEK2 inhibitors

Bibliography

• Collins I, Workman P. Design and development of signal transduction inhibitors for cancer treatment: experience and challenges with kinase targets. Curr Signal Trans Ther 2006;1:13-23
   Web of Science ®Google Scholar
• Gaestel M, Mengel A, Bothe U, Asadullah K. Protein kinases as small molecule inhibitor targets in inflammation. Curr Med Chem 2007;14:2214-34
   PubMed Web of Science ®Google Scholar
• Cohen P. Protein kinases: the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:309-15
   PubMed Web of Science ®Google Scholar
• Klebl BM, Müller G. Second-generation kinase inhibitors. Expert Opin Ther Targets 2005;9:975-93
   PubMed Web of Science ®Google Scholar
• Kéri G, Orfi L, Eros D, et al. Signal transduction therapy with rationally designed kinase inhibitors. Curr Signal Trans Ther 2006;1:67-95
   Google Scholar
• Avruch J. MAP kinase pathways: the first twenty years. Biochim Biophys Acta 2007;1773:1150-60
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold JS, Herrera R, Ohren JF. The mitogen-activated protein kinase pathway for molecular-targeted cancer treatment. Recent Results Cancer Res 2007;172:155-67
   PubMedGoogle Scholar
• Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47
   PubMed Web of Science ®Google Scholar
• Zebisch A, Czernilofsky AP, Keri G, et al. Signalling through RAS-RAF-MEK-ERK: from basics to bedside. Curr Med Chem 2007;14:601-23
   PubMed Web of Science ®Google Scholar
• Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005;6:827-38
   PubMed Web of Science ®Google Scholar
• Ma W, Quirion R. The ERK/MAPK pathway, as a target for the treatment of neuropathic pain. Expert Opin Ther Patents 2005;9:699-713
   Google Scholar
• Rogers DF. The role of airway secretions in COPD: pathophysiology, epidemiology and pharmacotherapeutic options. COPD 2005;2:341-53
   PubMedGoogle Scholar
• Senawong T, Phuchareon J, Ohara O, et al. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Hum Mol Genet 2008;17:419-30
   PubMed Web of Science ®Google Scholar
• Xie J, Ajibade AO, Ye F, et al. Reactivation of Kaposi's sarcoma-associated herpes virus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology 2008;371:139-54
   PubMedGoogle Scholar
• Hsieh H-P, Hsu JT-A. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des 2007;13:3531-42
   PubMedGoogle Scholar
• Lee JT, McCubrey JA. Targeting the Raf kinase cascade in the cancer therapy: novel molecular targets and therapeutic strategies. Expert Opin Ther Targets 2002;6:659-78
   PubMedGoogle Scholar
• Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 2005;5:350-6
   PubMed Web of Science ®Google Scholar
• Alessi DR, Cuenda A, Cohen P, et al. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-94
   PubMed Web of Science ®Google Scholar
• Warner-Lambert Co. 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders. WO9622985; 1996
   Google Scholar
• Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-32
   PubMed Web of Science ®Google Scholar
• Duncia JV, Santella JB III, Higley CA, et al. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclisation products. Bioorg Med Chem Lett 1998;8:2839-44
   PubMed Web of Science ®Google Scholar
• Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;11:1192-7
   PubMed Web of Science ®Google Scholar
• Metrangolo P, Neukirch H, Pilati T, Resnati G. Halogen bonding based recognition processes: a world parallel to hydrogen bonding. Acc Chem Res 2005;38:386-95
   PubMed Web of Science ®Google Scholar
• Auffinger P, Hays FA, Westhof E, Shing HOP. Halogen bonds in biological molecules. Proc Natl Acad Sci USA 2004;101:16789-94
   PubMed Web of Science ®Google Scholar
• Kiselyov A, Balakin KV, Tkachenko SE, Savchuk NP. Recent progress in the development of non-ATP competitive small-molecule inhibitors of protein kinases. Mini Rev Med Chem 2006;6:711-7
   PubMed Web of Science ®Google Scholar
• Bogoyevitch MA, Fairlie DP. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 2007;12:622-33
   PubMed Web of Science ®Google Scholar
• Fedorov O, Marsden B, Pogacic V, et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA 2007;104:20523-8
   PubMed Web of Science ®Google Scholar
• Wallace EM, Lyssikatos JP, Yeh T, et al. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr Top Med Chem 2005;5:215-29
   PubMed Web of Science ®Google Scholar
• Pheneger J, Wallace E, Marlow A. Characterisation of ARRY-438162, a potent MEK inhibitor in combination with methotrexate or ibuprofen in in vivo models of arthritis [abstract 794]. Arthritis Rheum 2006;54(9 Suppl)
   Google Scholar
• Pheneger J, Wallace E, Marlow A, et al. Characterisation of ARRY-438162, a potent MEK inhibitor in combination with methotrexate or ibuprofen in in vivo models of arthritis. Array BioPharma. 13 November 2006. Available at: http://www.arraybiopharma.com/_documents/Publication/PubAttachment199.pdf [Last accessed 14 May 2008]
   Google Scholar
• Spicer JA, Rewcastle GW, Kaufman MD, et al. 4-Anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase. J Med Chem 2007;50:5090-102
   PubMed Web of Science ®Google Scholar
• Krepinsky J, Wu D, Ingram A, et al. Developments in mitogen-induced extracellular kinase 1 inhibitors and their use in the treatment of disease. Expert Opin Ther Patents 2002;12:1795-811
   Web of Science ®Google Scholar
• Wang JY, Wilcoxen KM, Nomoto K. Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem 2007;7:1364-78
   PubMed Web of Science ®Google Scholar
• Warner-Lambert Co. Method of treating or preventing septic shock by administering a MEK inhibitor. WO9837881; 1998
   Google Scholar
• Warner-Lambert Co. 2-(4-Bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors. WO9901421; 1999
   Google Scholar
• Warner-Lambert Co. 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors. WO9901426; 1999
   Google Scholar
• Warner-Lambert Co. Use of a MEK inhibitor for preventing transplant rejection. WO0035435; 2000
   Google Scholar
• Warner-Lambert Co. Treatment of arthritis with MEK inhibitors. WO0035436; 2000
   Google Scholar
• Warner-Lambert Co. Combination chemotherapy. WO0037141; 2000
   Google Scholar
• Warner-Lambert Co. Treatment of asthma with MEK inhibitors. WO0040235; 2000
   Google Scholar
• Warner-Lambert Co. Antiviral method using MEK inhibitors. WO2040237; 2000
   Google Scholar
• Warner-Lambert Co. 4′-Heteroaryl diarylamines. WO0041505; 2000
   Google Scholar
• Warner-Lambert Co. 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors. WO0041994; 2000
   Google Scholar
• Warner-Lambert Co. Sulphohydroxamic acids and sulphohydroxamates and their use as MEK inhibitors. WO0042002; 2000
   Google Scholar
• Warner-Lambert Co. Benzenesulfonamide derivatives and their use as MEK inhibitors. WO0042003; 2000
   Google Scholar
• Warner-Lambert Co. Benzoheterocycles and their use as MEK inhibitors. WO0042022; 2000
   Google Scholar
• Warner-Lambert Co. 1-Heterocycle substituted diarylamines. WO0042029; 2000
   Google Scholar
• Warner-Lambert Co. Method for treating chronic pain using MEK inhibitors. WO0105390; 2001
   Google Scholar
• Warner-Lambert Co. Method for treating chronic pain using MEK inhibitors. WO0105391; 2001
   Google Scholar
• Warner-Lambert Co. Method for treating chronic pain using MEK inhibitors. WO0105392; 2001
   Google Scholar
• Warner-Lambert Co. Method for treating chronic pain using MEK inhibitors. WO0105393; 2001
   Google Scholar
• Warner-Lambert Co. 5-Amide substituted diarylamines as MEK inhibitors. WO0168619; 2001
   Google Scholar
• Warner-Lambert Co. Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids. WO0206213; 2002
   Google Scholar
• Warner-Lambert Co. LLC. N-(4-substituted phenyl)-anthranilic acid hydroxamate esters. WO03062189; 2003
   Google Scholar
• Warner-lambert co. LLC. N-(4-substituted phenyl)-anthranilic acid hydroxamate esters. WO03062191; 2003
   Google Scholar
• Warner-Lambert Co. LLC. MEK inhibitors oxa- and thia-diazol-2-yl-phenylamine derivatives. WO04056789; 2004
   Google Scholar
• Warner-Lambert Co. LLC. 5-Substituted-4′-(substituted phenyl)amino-2-pyridone derivatives for use as MEK inhibitors. WO05000818; 2005
   Google Scholar
• Warner-Lambert Co. LLC. Diphenylamino ketone derivatives as MEK inhibitors. WO05007616; 2005
   Google Scholar
• Warner-Lambert Co. LLC. N-Methyl-substituted benzamidazoles. WO05009975; 2005
   Google Scholar
• Warner-Lambert Co. LLC. Imidazopyridines and triazolopyridines. US050049276; 2005
   Google Scholar
• Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors. WO03077855; 2003
   Google Scholar
• Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors. WO03077914; 2003
   Google Scholar
• Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007;13:1576-83
   PubMed Web of Science ®Google Scholar
• Lyssikatos J. AZD6244 (ARRY-142886) a novel and highly selective MEK inhibitor in clinical trials. Array BioPharma. 3 April 2006. Available at: http://www.arraybiopharma.com/_documents/Publication/PubAttachment179.pdf [Last accessed 14 May 2008]
   Google Scholar
• Array Biopharma, Inc./Astrazeneca AB. Tosylate salt of 6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzimidazole-5-carboxamide, MEK inhibitor useful in the treatment of cancer. WO07071951; 2007
   Google Scholar
• Array Biopharma, Inc./Astrazeneca AB. Novel hydrogen sulphate salt. WO07076245; 2007
   Google Scholar
• Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors. WO05023251; 2005
   Google Scholar
• Array Biopharma, Inc. Heterocyclic inhibitors of MEK and methods of use thereof. WO05023759; 2005
   Google Scholar
• Array Biopharma, Inc. Method of treating inflammatory diseases. WO07022529; 2006
   Google Scholar
• Lee P, Wallace E, Bendele A, et al. In vivo activity of potent MEK inhibitors in two models of inflammatory disease. Array BioPharma. 23 August 2005. Available at: http://www.arraybiopharma.com/_documents/Publication/PubAttachment105.pdf [Last accessed 14 May 2008]
   Google Scholar
• Array Biopharma, Inc. Heterocyclic inhibitors of MEK and methods of use thereof. WO05051906; 2005
   Google Scholar
• Array Biopharma, Inc. Bicyclic inhibitors of MEK and methods of use thereof. WO05051302; 2005
   Google Scholar
• Array Biopharma, Inc. Bicyclic inhibitors of MEK and methods of use thereof. WO05051300; 2005
   Google Scholar
• Array Biopharma, Inc. Heterocyclic inhibitors of MEK and methods of use thereof. WO05051301; 2005
   Google Scholar
• Wallace EM, Lyssikatos J, Blake JF, et al. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-Bromo-2-flourophenylamino)-1-methylpyridin-2(1H)-ones. J Med Chem 2006;49:441-4
   PubMed Web of Science ®Google Scholar
• Wallace EM, Lyssikatos J, Blake JF, et al. 4-(4-Bromo-2-fluorophenylamino)- 1-methyl-pyridin-2(1H)ones: potent and selective MEK 1,2 inhibitors. Array BioPharma. 16 November 2005. Available at: http://www.arraybiopharma.com/_documents/Publication/PubAttachment128.pdf [Last accessed 15 May 2008]
   Google Scholar
• Array Biopharma, Inc./Astrazeneca AB. Heterocyclic inhibitors of MEK and methods of use thereof. WO07044084; 2007
   Google Scholar
• Sankyo. Sulfamide derivative and medicinal composition thereof. WO04083167; 2004
   Google Scholar
• Chugai Seiyaku Kabushiki. Novel 4-phenylamino-benzaldoxime derivative and use thereof as MEK inhibitor. WO05028426; 2005
   Google Scholar
• Chugai Seiyaku Kabushiki. 5-Substituted-2-phenylamino-benzamide as MEK inhibitor. WO06011466; 2006
   Google Scholar
• Japan Tobacco, Inc. 5-Amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido-2,3-D pyrimidine derivatives and related compounds for the treatment of cancer. WO05121142; 2005
   Google Scholar
• Zhang W, Ricketts W, An H, Hong Z. Heterocyclic compounds and uses thereof. US040039037; 2004
   Google Scholar
• Varaprasad CVNS, Barawkar D, Abdellaoui HE, et al. Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors. Bioorg Med Chem Lett 2006;16:3975-80
   PubMed Web of Science ®Google Scholar
• Valeant Pharmaceuticals International. Phenylamino isothiazole carboxamidines as MEK inhibitors. WO06133417; 2006
   Google Scholar
• Abdellaoui HE, Varaprasad CVNS, Barawkar D, et al. Identification of isothiazole-4-carboxamidine derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg Med Chem Lett 2006;16:5561-6
   PubMedGoogle Scholar
• Valeant Research & Development. N-(arylamino)-sulfonamide inhibitors of MEK. WO07014011; 2007
   Google Scholar
• Ardea Biosciences, Inc. N-aryl-N′-alkyl sulfamides as MEK inhibitors. WO07121269; 2007
   Google Scholar
• Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors. WO07121481; 2007
   Google Scholar
• Applied Research Systems ARS Holdings NV. 3-Arylamino pyridine derivatives. WO06045514; 2006
   Google Scholar
• Applied Research Systems ARS Holdings NV. Novel 4-arylamino pyridone derivatives as MEK inhibitors for the treatment of hyperproliferative disorders. WO06056427; 2006
   Google Scholar
• Applied Research Systems ARS Holdings NV. [1,2,4]-Triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases. WO06058752; 2006
   Google Scholar
• Applied Research Systems ARS Holdings NV. Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors. WO07123936; 2007
   Google Scholar
• Applied Research Systems ARS Holdings NV. Novel arylamino N-heteraryls as MEK inhibitors. WO07123939; 2007
   Google Scholar
• Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases. WO20044515; 2007
   Google Scholar
• UCB Pharma SA. Thieno-pyridine derivatives as MEK inhibitors. WO07088345; 2007
   Google Scholar
• UCB Pharma SA. Fused thiophene derivatives as MEK inhibitors. WO08020206; 2008
   Google Scholar
• Dupont Pharmaceuticals Co. Amino-thio-acrylonitriles as MEK inhibitors. WO0056706; 2000
   Google Scholar
• Wityak J, Hobbs FW, Gardner DS, et al. Beyond U0126: dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors. Bioorg Med Chem Lett 2004;14:1483-6
   PubMed Web of Science ®Google Scholar
• Applied Research Systems ARS Holdings NV. Pharmaceutically active compounds and methods of use. WO003035626; 2003
   Google Scholar
• Karra S, Goutopoulos A, Sutton A, et al. Novel N-substituted imidazole based non-ATP competitive MEK inhibitors as potential anticancer agents. Proc Am Assoc Cancer Res 2007;48:5411
   Google Scholar
• F Hoffmann-La Roche AG. Substituted hydantoins. WO06018188; 2006
   Google Scholar
• F Hoffmann-La Roche AG. Substituted hydantoins for the treatment of cancer. WO06029862; 2006
   Google Scholar
• F Hoffmann-La Roche AG. Hydantoin based kinase inhibitors. WO07096259; 2007
   Google Scholar
• Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23:5281-93
   PubMed Web of Science ®Google Scholar
• Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22:4456-62
   PubMed Web of Science ®Google Scholar
• Lorusso P, Krishnamurthi S, Rinehart JR, et al. A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901, in patients with advanced cancer. J Clin Oncol 2005;23:3011
   Web of Science ®Google Scholar
• Menon SS, Whitfield LR, Sadis S, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients. J Clin Oncol 2005;23:3066
   Web of Science ®Google Scholar
• Lorusso P, Krishnamurthi S, Rinehart J, et al. Clinical aspects of a phase I study of PD-0325901, a selective oral MEK inhibitor, in patients with advanced cancer [abstract B113]. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets in Cancer Therapy; 2007 October 22 – 26
   Google Scholar
• Pfizer pipeline - as of July 31, 2007. Pfizer Research and Development. Available at: http://www.pfizer.com/research/pipeline/pipeline.jsp [Last accessed 15 May 2008]
   Google Scholar
• Pfizer pipeline - as of 28 February 2008. Pfizer Research and Development. Available at: http://www.pfizer.com/research/pipeline/pipeline.jsp [Last accessed 20 May 2008]
   Google Scholar
• Topline Results Announced from a Phase 2 Study in Advanced Melonoma of Investigational Anti-Cancer Drug AZD6244 (ARRY-886). Array BioPharma. press release. 19 December 2007. Available at: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1088941&highlight [Last accessed 15 May 2008]
   Google Scholar
• Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008;14:342-6
   PubMed Web of Science ®Google Scholar
• Wang D, Boerner SA, Winkler JD, Lorusso PM. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 2007;1773:1248-55
   PubMed Web of Science ®Google Scholar
• Array BioPharma Achieves Milestone for Dosing MEK Inhibitor, ARRY-704, in Phase 1 Clinical Trial. Array BioPharma. press release. 12 April 2007. Available at: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=984048&highlight [Last accessed 15 May 2008]
   Google Scholar
• Exelixis Announces Second Quarter 2007 Financial Results and Business Update. Exelixis. press release. 7 August 2007. Available at: http://ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-newsArticle&ID=1037816&highlight=XL518 [Last accessed 15 May 2008]
   Google Scholar
• New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties. Ardea Biosciences. press release. 24 October 2007. Available at: http://investorcenter.ardeabio.com/releasedetail.cfm?ReleaseID=271328 [Last accessed 15 May 2008]
   Google Scholar
• Hamatake R, Iverson C, Yeh L-T, et al. RDEA119, a potent and highly specific MEK inhibitor is efficacious in mouse tumor xenograft studies. Ardea Biosciences. 15 April 2008. Available at: http://www.ardeabio.com/Docs/RDEA119 A Potent and Highly Specific MEK.pdf [Last accessed 20 May 2008]
   Google Scholar
• Merck Serono pipeline - as of February 2008. Merck Serono. Available at: http://www.merckserono.net/en/merck_serono/how_we_innovate/pipeline/pipeline.jsp#0 [Last accessed 15 May 2008]
   Google Scholar
• Johnston S. XL518, a potent, selective orally bioavailable MEK1 inhibitor, down-regulates the Ras/Raf/MEK/ERK pathway in vivo, resulting in tumor growth inhibition and regression in preclinical models [abstract C209]. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets in Cancer Therapy; 2007 October 22 – 26
   Google Scholar
• Weingarten P, Iverson C, Hamatake R, et al. RDEA119: a potent and highly selective MEK inhibitor for the treatment of cancer [abstract B120]. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets in Cancer Therapy; 2007 October 22 – 26
   Google Scholar
• Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006;5:649-59
   PubMed Web of Science ®Google Scholar
• Djahansouzi S, Heimerzheim T, Reinhart M, et al. Therapeutic doses of tamoxifen only partially inhibit the non-genomic effects of estrogen: evidence for additive anti-proliferative effect of tamoxifen with MEK inhibitor. J Clin Oncol 2005;23:3195
   Google Scholar
• Edwards LA, Verrault M, Thiessen B, et al. Combined inhibition of the phosphatidyl 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther 2006;5:645-54
   PubMed Web of Science ®Google Scholar
• Yu C, Dasmahapatra G, Dent P, Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL + human leukemia cells. Leukemia 2005;19:1579-89
   PubMed Web of Science ®Google Scholar
• Normano N, De Luca A, Maiello MR, et al. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor Gefitinib. J Cell Physiol 2006;207:420-7
   PubMedGoogle Scholar
• Milella M, Precupanu CM, Gregorj C, et al. Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des 2005;11:2779-95
   PubMed Web of Science ®Google Scholar
• McDaid HM, Lopez-Barcons L, Grossman A, et al. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res 2005;65:2854-60
   PubMed Web of Science ®Google Scholar
• Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6:2209-19
   PubMed Web of Science ®Google Scholar
• Haass NK, Sproesser K, Nguyen TK, et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008;14:230-9
   PubMed Web of Science ®Google Scholar
• A Phase I, Open-Label, Multi-Center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886). Clinical Trials.gov. 15 May 08. Available at: http://clinicaltrials.gov/ct2/show/NCT00600496?term=AZD6244&rank=1 [Last accessed 15 May 2008]
   Google Scholar
• Significant Development: Array BioPharma and AstraZeneca Announce New Phase 2 Development Plans for the Investigational Anti-Cancer Drug AZD6244 (ARRY-886). Array BioPharma. 15 May 2008. Available at: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1146506&highlight>= [Last accessed 20 May 2008]
   Google Scholar
• Winkler J, Lee P, Pheneger J, et al. ARRY-162, a selective, potent inhibitor of MEK1/2, shows ex vivo inhibition of cytokine production in clinical trials. Array BioPharma. 29 January 2007. Available at: http://www.arraybiopharma.com/_documents/Publication/PubAttachment227.pdf [Last accessed 15 May 2008]
   Google Scholar
• Koch K, Winkler J, Pheneger J, et al. ARRY-162, a selective, potent MEK1/2 inhibitor, significantly reduces ex vivo IL-1-beta and TNF-alpha production in normal subjects [abstract SAT0051]. Ann Rheum Dis 2007;66(Suppl 2)
   Google Scholar
• Koch K, Winkler J, Pheneger J, et al. ARRY-162, a selective, potent MEK 1/2 inhibitor, significantly reduces ex vivo IL-1(beta) and TNF-(alpha) production in normal subjects. Array BioPharma. 16 June 2007. Available at: http://www.arraybiopharma.com/_documents/Publication/PubAttachment229.pdf [Last accessed 15 May 2008]
   Google Scholar
• Winkler JD. ARRY-162, a selective, potent MEK1/2 inhibitor, significantly reduces ex vivo IL-1 and TNF production in normal subjects [abstract FC11.4]. Inflamm Res 2007;56(Suppl 3)
   Google Scholar
• Winkler JD. ARRY-162, a selective, potent MEK 1/2 inhibitor, significantly reduces ex vivo IL-1 and TNF production in normal human subjects. Array BioPharma. 20 June 2007. Available at: http://www.arraybiopharma.com/_documents/Publication/PubAttachment239.pdf [Last accessed 15 May 2008]
   Google Scholar
• Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2008. Array BioPharma. press release. 4 February 2008. Available at: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1104094&highlight [Last accessed 15 May 2008]
   Google Scholar